Overview

• US oncology device maker's Q1 2026 revenue rose 186% yr/yr on expanding cancer center adoption

• Net loss widened to $3.5 mln from $2.4 mln a year earlier

• Company ended Q1 with $12.4 mln in cash after $10 mln private placement

Outlook

• RenovoRx reiterates full-year 2026 revenue guidance of $3 mln to $4 mln

• Company expects continued revenue growth in 2026 as more cancer centers are activated

• RenovoRx targets 36 active commercial cancer centers by year-end 2026

Result Drivers

• CANCER CENTER EXPANSION - Revenue growth mainly driven by increase in active commercial cancer center customers and higher procedural utilization

• REPEAT UTILIZATION - Company observed meaningful repeat ordering from existing centers, indicating physician confidence and clinical utility

Company press release: ID:nGNX9SSfhJ

Key Details

Metric	Beat/Miss	Actual	Consensus Estimate
Q1 Net Income		-$3.52 mln

Analyst Coverage

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

• Wall Street's median 12-month price target for RenovoRx Inc is $5.50, about 548.1% above its May 13 closing price of $0.85

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.